AMPH Amphastar Pharmaceuticals, Inc.

+0  (1%)
Previous Close 14.51
Open 14.56
Price To book 2.04
Market Cap 672.58M
Shares 45,910,000
Volume 213,446
Short Ratio 5.30
Av. Daily Volume 365,316

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Albuterol DPI
CRL announced February 21, 2017.
Naloxone Intranasal
Opioid overdose
CRL issued December 27, 2016.
Primatene Mist (epinephrine inhalation aerosol)

Latest News

  1. Amphastar Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
  2. Blog Coverage Sonoma Pharmaceuticals Announced FDA Clearance for Loyon Skin Descaler
  3. ETFs with exposure to Amphastar Pharmaceuticals, Inc. : March 27, 2017
  4. Amphastar Pharmaceuticals, Inc. :AMPH-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  5. Edited Transcript of AMPH earnings conference call or presentation 13-Mar-17 9:00pm GMT
  6. Amphastar reports 4Q loss
  7. Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Fiscal Year Ended December 31, 2016
  8. Williams-Sonoma Among 5 Earnings Plays That Could Squeeze the Shorts
  9. Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 13, 2017
  10. Drug Addiction Treatment Stocks to Watch
  11. Amphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMPH-US : February 22, 2017
  12. FDA Rejects Amphastar's Nasal Opioid Overdose Drug
  13. Amphastar Pharma stock plummets 16% after FDA fails to approve nasal spray for opioid overdoses
  14. FDA rejects Amphastar's nasal version of opioid overdose treatment
  15. Amphastar Announces the Receipt of a CRL for Intranasal Naloxone for the Emergency Treatment of Opioid Overdose
  16. Lifshitz & Miller Law Firm Announces Investigation of Ally Financial Inc., Amphastar Pharmaceuticals, Inc., Lannett Company, Inc., Live Ventures Incorporated, MiMedx Group, Inc., Seattle Genetics, Inc., Teligent, Inc., TerraVia Holdings, Inc., and Zimmer Biomet Holdings, Inc.
  17. 6 Major FDA Decisions and Biopharma Catalysts Coming in January and February
  18. IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Amphastar Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
  19. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amphastar Pharmaceuticals, Inc. - AMPH